Bronchospasm Prevention With Copd — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bronchospasm prevention with copd. 127 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
127
Active US patents
63/100
Avg vulnerability
$2.6B
Annual revenue covered

Originators in Bronchospasm Prevention With Copd

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Boehringer Ingelheim 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bronchospasm prevention with copd. Each bar = one year. Y-axis scaled to peak year (30 patents).

4
26
3
27
2
28
1
30
30
31
8
34
15
35
8
36
21
39
28
40
7
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Spiriva
TIOTROPIUM BROMIDE
 Boehringer Ingelheim 9 68 $2.5B 2026-07-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12083270 Cutivate method of use 81 2031-04-04
8022082 Spiriva other 80 2026-07-19
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
7396341 Spiriva other 80 2027-04-10
9027967 Spiriva other 75 2027-09-30
7837235 Spiriva other 75 2028-09-13
11554229 Cutivate method of use 70 2036-02-23
8733341 Spiriva other 68 2031-04-16
10195375 Cutivate other 68 2031-08-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14

Related